Calcium reduces CRC risk
As reported in the International Journal of Cancer, there is an 8% reduction in CRC risk with each 300 mg/d increase in calcium intake based on 15 studies involving 12305 patients who took 250-1900 mg of calcium/day over a 3.3-16 year follow-up period. The beneficial effect extended beyond 1000 mg/d.
Infliximab is effective in corticosteroid-refractory ulcerative colitis
As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.
Increased MMP-9 expression associated with poor prognosis in CRC
As reported in the World Journal of Surgical Oncology, the expression of MMP-9 in colon cancer tissues was increased compared to distal normal mucosa (69.1% vs. 2.9%). Increased MMP-9 expression was associated with lymph node metastasis, Duke stage, and decreased survival.